Clinical trial
Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who…
NCT00338949 · Veterans Medical Research Foundation, Other · Completed
Key facts
| NCT number | NCT00338949 |
|---|---|
| Title | Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes |
| Official title | The Metabolic Syndrome in Patients With Schizophrenia |
| Lead sponsor | Veterans Medical Research Foundation, Other |
| Collaborators | National Institute of Mental Health (NIMH) NIH Pfizer Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Metabolic Syndrome X, Insulin Resistance |
| Intervention type | Drug |
| Interventions | Switch, Control |
| Enrollment | 77 |
| Start date | Jun 1, 2006 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Jun 20, 2006 |
| Last update posted | Oct 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: